275 related articles for article (PubMed ID: 21959291)
1. Primary prophylaxis for Pneumocystis jirovecii pneumonia in patients with connective tissue diseases.
Vananuvat P; Suwannalai P; Sungkanuparph S; Limsuwan T; Ngamjanyaporn P; Janwityanujit S
Semin Arthritis Rheum; 2011 Dec; 41(3):497-502. PubMed ID: 21959291
[TBL] [Abstract][Full Text] [Related]
2. Positivity for anti-RNP antibody is a risk factor for adverse effects caused by trimethoprim-sulfamethoxazole, a prophylactic agent for P. jiroveci pneumonia, in patients with connective tissue diseases.
Maezawa R; Kurasawa K; Arai S; Okada H; Owada T; Fukuda T
Mod Rheumatol; 2013 Jan; 23(1):62-70. PubMed ID: 22466117
[TBL] [Abstract][Full Text] [Related]
3. Efficacies of atovaquone, pentamidine, and trimethoprim/sulfamethoxazole for the prevention of Pneumocystis jirovecii pneumonia in patients with connective tissue diseases.
Kitazawa T; Seo K; Yoshino Y; Asako K; Kikuchi H; Kono H; Ota Y
J Infect Chemother; 2019 May; 25(5):351-354. PubMed ID: 30711257
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of sulfamethoxazole-trimethoprim administration in the prevention of Pneumocystis carinii pneumonia in patients with connective tissue disease.
Okada J; Kadoya A; Rana M; Ishikawa A; Iikuni Y; Kondo H
Kansenshogaku Zasshi; 1999 Nov; 73(11):1123-9. PubMed ID: 10624092
[TBL] [Abstract][Full Text] [Related]
5. Atovaquone versus trimethoprim-sulfamethoxazole as Pneumocystis jirovecii pneumonia prophylaxis following renal transplantation.
Gabardi S; Millen P; Hurwitz S; Martin S; Roberts K; Chandraker A
Clin Transplant; 2012; 26(3):E184-90. PubMed ID: 22487221
[TBL] [Abstract][Full Text] [Related]
6. Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials.
Green H; Paul M; Vidal L; Leibovici L
Mayo Clin Proc; 2007 Sep; 82(9):1052-9. PubMed ID: 17803871
[TBL] [Abstract][Full Text] [Related]
7. Pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 cases.
Godeau B; Coutant-Perronne V; Le Thi Huong D; Guillevin L; Magadur G; De Bandt M; Dellion S; Rossert J; Rostoker G; Piette JC
J Rheumatol; 1994 Feb; 21(2):246-51. PubMed ID: 8182632
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of once-weekly dapsone dosing for Pneumocystis jirovecii pneumonia prophylaxis post transplantation.
Evans RA; Clifford TM; Tang S; Au T; Fugit AM
Transpl Infect Dis; 2015 Dec; 17(6):816-21. PubMed ID: 26369753
[TBL] [Abstract][Full Text] [Related]
9. High rates of Pneumocystis carinii pneumonia in allogeneic blood and marrow transplant recipients receiving dapsone prophylaxis.
Souza JP; Boeckh M; Gooley TA; Flowers ME; Crawford SW
Clin Infect Dis; 1999 Dec; 29(6):1467-71. PubMed ID: 10585797
[TBL] [Abstract][Full Text] [Related]
10. Successful prophylaxis against Pneumocystis carinii pneumonia in HIV-infected children using smaller than recommended dosages of trimethoprim-sulfamethoxazole.
Fisher RG; Nageswaran S; Valentine ME; McKinney RE
AIDS Patient Care STDS; 2001 May; 15(5):263-9. PubMed ID: 11530767
[TBL] [Abstract][Full Text] [Related]
11. Pneumocystis carinii pneumonia in patients with connective tissue disease.
Li J; Huang XM; Fang WG; Zeng XJ
J Clin Rheumatol; 2006 Jun; 12(3):114-7. PubMed ID: 16755237
[TBL] [Abstract][Full Text] [Related]
12. Comparison of trimethoprim-sulfamethoxazole and aerosolized pentamidine for primary prophylaxis of Pneumocystis jiroveci pneumonia in immunocompromised patients with connective tissue disease.
Kimura M; Tanaka S; Ishikawa A; Endo H; Hirohata S; Kondo H
Rheumatol Int; 2008 May; 28(7):673-6. PubMed ID: 18080124
[TBL] [Abstract][Full Text] [Related]
13. A dose-escalation regimen of trimethoprim-sulfamethoxazole is tolerable for prophylaxis against Pneumocystis jiroveci pneumonia in rheumatic diseases.
Takenaka K; Komiya Y; Ota M; Yamazaki H; Nagasaka K
Mod Rheumatol; 2013 Jul; 23(4):752-8. PubMed ID: 22907597
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of prophylaxis for Pneumocystis jirovecii pneumonia involving trimethoprim-sulfamethoxazole dose reduction in kidney transplantation.
Prasad GVR; Beckley J; Mathur M; Gunasekaran M; Nash MM; Rapi L; Huang M; Zaltzman JS
BMC Infect Dis; 2019 Apr; 19(1):311. PubMed ID: 30953458
[TBL] [Abstract][Full Text] [Related]
15. Preventive effect of sulfamethoxasole-trimethoprim on Pneumocystis jiroveci pneumonia in patients with interstitial pneumonia.
Enomoto T; Azuma A; Matsumoto A; Nei T; Fujita K; Hattori K; Saito Y; Abe S; Usuki J; Kudoh S
Intern Med; 2008; 47(1):15-20. PubMed ID: 18175999
[TBL] [Abstract][Full Text] [Related]
16. Acute psychosis related to use of trimethoprim/sulfamethoxazole in the treatment of HIV-infected patients with Pneumocystis jirovecii pneumonia: a multicentre, retrospective study.
Lee KY; Huang CH; Tang HJ; Yang CJ; Ko WC; Chen YH; Lee YC; Hung CC
J Antimicrob Chemother; 2012 Nov; 67(11):2749-54. PubMed ID: 22821870
[TBL] [Abstract][Full Text] [Related]
17. Prophylactic antibiotic usage for Pneumocystis jirovecii pneumonia in patients with systemic lupus erythematosus on cyclophosphamide: a survey of US rheumatologists and the review of literature.
Gupta D; Zachariah A; Roppelt H; Patel AM; Gruber BL
J Clin Rheumatol; 2008 Oct; 14(5):267-72. PubMed ID: 18679133
[TBL] [Abstract][Full Text] [Related]
18. [Pneumocystis pneumonia in patients with immunosuppression other than HIV infection].
Adler D; Chenivesse C; Similowski T; Soccal PM
Rev Med Suisse; 2008 Nov; 4(180):2525-6, 2528-30. PubMed ID: 19127897
[TBL] [Abstract][Full Text] [Related]
19. Single-day trimethoprim/sulfamethoxazole prophylaxis for Pneumocystis pneumonia in children with cancer.
Caselli D; Petris MG; Rondelli R; Carraro F; Colombini A; Muggeo P; Ziino O; Melchionda F; Russo G; Pierani P; Soncini E; DeSantis R; Zanazzo G; Barone A; Cesaro S; Cellini M; Mura R; Milano GM; Meazza C; Cicalese MP; Tropia S; De Masi S; Castagnola E; Aricò M;
J Pediatr; 2014 Feb; 164(2):389-92.e1. PubMed ID: 24252793
[TBL] [Abstract][Full Text] [Related]
20. Pneumocystis pneumonia in patients with rheumatic diseases receiving prolonged, non-high-dose steroids-clinical implication of primary prophylaxis using trimethoprim-sulfamethoxazole.
Park JW; Curtis JR; Kim MJ; Lee H; Song YW; Lee EB
Arthritis Res Ther; 2019 Sep; 21(1):207. PubMed ID: 31521185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
